A PCSK9 Inhibitor in a Pill: What Lipfendra Changes—and What It Doesn’t

Lipfendra is officially FDA-approved, giving patients something they haven’t had before: an oral PCSK9 inhibitor for lowering LDL, or “bad,” cholesterol.

As a physician, I’m always glad to see patients get more treatment options. And there’s plenty to be excited about here. PCSK9 inhibitors are exceptionally effective at lowering LDL, and putting that mechanism into a pill could make this class more approachable for patients who don’t want an injection.

But there’s an important distinction I think is getting lost in the excitement around a new oral option: Lowering cholesterol is not the ultimate goal. Preventing heart attacks and strokes is.

For plan sponsors evaluating where Lipfendra fits into their pharmacy strategy, that distinction matters.

First, Why Is an Oral PCSK9 Inhibitor a Big Deal?

PCSK9 inhibitors aren’t new. Repatha and Praluent are both injectable PCSK9 inhibitors already on the market. There’s also Leqvio, an injectable treatment that works through a different mechanism targeting PCSK9 and is administered by a healthcare professional every six months.

What makes Lipfendra different is simple: It’s a pill.

And that matters. Some patients simply don’t want an injectable medication. Giving those patients an oral alternative can remove a barrier to treatment.

The other reason for the excitement is efficacy. PCSK9 inhibitors can produce dramatic reductions in LDL, which makes them valuable for patients who need to reach particularly aggressive cholesterol targets.

But here's where I want plan sponsors to look beyond the headline.

Lower LDL Is Great. But That’s Not the Finish Line.

We've learned a lot about cholesterol treatment over the past few decades.

There was a time when the thinking was fairly straightforward: Get a patient's cholesterol down, by whatever means necessary, and you've solved the problem.

We now know it's more complicated than that. Making a lab value better doesn't always mean you've improved the outcome you're ultimately trying to prevent. That's particularly important when comparing a brand-new medication with treatments that have been studied for years.

Lipfendra has demonstrated that it can significantly lower LDL. That's important, and it's what the drug needed to establish as part of its FDA approval.

What we don't have yet is the same depth of long-term cardiovascular outcomes data that exists for some established therapies.

Repatha, for example, has compelling outcomes data demonstrating that it can reduce cardiovascular events in appropriate high-risk patients. And statins have decades of evidence showing that they reduce the risk of heart attack and stroke.

Lipfendra may ultimately demonstrate those benefits, too. But those studies take time.

If I'm treating someone who has already had a heart attack, that's not an insignificant distinction.

Do I want a medication that I know lowers LDL? Absolutely. But I also want to know whether we've proven that it lowers that patient's risk of another heart attack.

The number matters. The outcome matters more.

Most Patients Still Have an Affordable Place to Start

Here's the other piece of this conversation that I think is easy to overlook: The potential population of people with high cholesterol is enormous.

The population that actually needs an expensive PCSK9 inhibitor is much smaller.

That's because we already have very good – and very inexpensive – cholesterol medications.

I'm talking primarily about statins. Most patients do well on them. They're widely available as generics. And unlike many newer medications, we have years and years of outcomes data demonstrating that they work.

For your average patient, an LDL goal might be below 100 mg/dL. For someone who has already had a heart attack or stroke, or who is at very high cardiovascular risk, we may be aiming much lower, sometimes below 65 mg/dL. That's where the treatment pathway starts to separate.

If a patient can reach the appropriate goal with a statin, that's generally a very effective and affordable solution.

If they can't tolerate statins, which does happen, or their LDL remains too high despite appropriate treatment, then we start looking at additional options. That's where PCSK9 inhibitors can become extremely valuable.

This Isn't About Keeping Patients Away From Expensive Drugs

I want to be clear about that, because it's an important distinction for plan sponsors. The answer to rising pharmacy costs isn't simply, “Use the cheapest drug.” And it isn't, “Don't cover the new drug.”

It's making sure the right patient gets to the right medication at the right time.

If a $5 generic statin can safely and effectively get a member to their clinical goal, that's a win for the patient and the plan.

If that statin doesn't work, isn't tolerated or can't get a high-risk patient where they need to be, then a more advanced therapy may absolutely be worth the additional cost.

That's the clinical logic we should be applying, not starting with price and working backward.

More Choice Makes Navigation More Important, Not Less

Lipfendra adds another option. That's good news.

It also adds another decision for members, prescribers and plan sponsors to navigate.

Now you're potentially comparing an oral PCSK9 inhibitor with injectable PCSK9 therapies, statins and other cholesterol-lowering medications, each with different evidence, costs, coverage requirements and patient considerations.

And the newest or most convenient option isn't automatically the best one.

This is where I think plan sponsors need to be especially thoughtful.

You want members who can improve their health outcomes on established, lower-cost therapies to find those options. You also want the members who genuinely need advanced treatment to have access to it without unnecessary friction.

And once you've determined that several options are clinically reasonable, you want to understand what each one will actually cost that specific member and the plan.

That's exactly the kind of complexity Rx Navigation should solve.

The Bigger Lesson for Plan Sponsors

I expect we're going to keep seeing innovation like Lipfendra. More oral medications, more specialty therapies and more competition within already crowded drug classes are coming.

That's a good thing for patients.

But more medications don't automatically lead to smarter prescription choices.

Plan sponsors need a way to evaluate the clinical evidence, understand where a medication belongs in the treatment pathway, identify lower-cost options when they're appropriate and help members actually act on those opportunities with their prescribers.

Lipfendra is exciting because it gives patients another choice.

But at the end of the day, I'm less interested in whether we have another way to lower someone's cholesterol than I am in whether we're helping that person avoid a heart attack or stroke.

That's the outcome that matters.

And that's the standard we should keep applying as every new medication enters the market.